• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Klaria Pharma Holding AB: Klaria Interim Report Q2 2025

Klaria Pharma Holding
Download the release

Klaria interim report

1 April-30 June 2025

Summary of the interim report

Second quarter of 2025

The group in total

- Net sales 0.0 MSEK (0.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 7.1 MSEK (3.6 MSEK)

- Profit after tax amounted to -20.1 MSEK (-12.4 MSEK)

- Earnings per share for the quarter amounted to -0.14 SEK (-0.11 SEK)

- Cash flow from operating activities amounted to -2.3 MSEK (-1.9 MSEK)

- Liquid assets on the balance sheet date amounted to 2.0 MSEK (1.5 MSEK)

- Group equity as of June 30 amounted to -18.4 MSEK (20.8 MSEK)

- Equity in the parent company as of June 30 amounted to 64.9 MSEK 142.6 MSEK)

The period January-June 2025

The group in total

- Net sales 9.0 MSEK (0.1 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 10.5 MSEK (8.2 MSEK)

- Profit after tax amounted to -21.7 MSEK (-24.3 MSEK)

- Earnings per share for the quarter amounted to -0.15 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -1.7 MSEK (-9.8 MSEK)